BACKGROUND: Asthma attacks are heterogeneous. It is not known whether the response to oral corticosteroids (OCS) in acute asthma varies according to type-2 (T2) inflammatory biomarkers, blood eosinophil count (BEC) and exhaled nitric oxide (FeNO). We aim to explore the relationship between T2 biomarkers and response to OCS in acute asthma. METHODS: We conducted a longitudinal observational study of people experiencing an asthma attack evaluated before and after a 7-day OCS course. The primary outcome was post-bronchodilator (BD) FEV RESULTS: Fifty-three people were enrolled with 16 (30%) T2-Low/Low, 27 (51%) T2-Mid and 10 (19%) T2-High/High asthma attacks. Post-BD FEV CONCLUSIONS: We found that objective improvement following OCS is confined to T2-High/High events. As in chronic asthma, greater T2 burden identifies a distinct clinical and therapeutic trajectory, whereas OCS-related adverse events are uniformly distributed.